Alzamend Neuro is trading 16.4% down at $1.01 in pre-market as the stock reverses its recent macro-driven rally.
- On July 14, 2026, the stock closed up about 5% as growth names bounced on softer U.S. inflation data and easing risk-off sentiment tied to U.S.–Iran tensions.
- With no new company-specific news reported this morning, the sharp pre-market drop appears to be a reversal of the prior day's short-term macro-driven move.